IQVIA Holdings Inc. (NYSE:IQV) Sees Large Decrease in Short Interest

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 3,110,000 shares, a decrease of 6.9% from the November 15th total of 3,340,000 shares. Based on an average trading volume of 1,510,000 shares, the short-interest ratio is currently 2.1 days. Currently, 1.7% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Oddo BHF Asset Management Sas bought a new position in shares of IQVIA during the 3rd quarter worth approximately $2,771,000. Franklin Resources Inc. raised its holdings in shares of IQVIA by 1.2% during the 3rd quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company’s stock worth $117,031,000 after buying an additional 6,011 shares in the last quarter. Tidal Investments LLC raised its holdings in shares of IQVIA by 9.3% during the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock worth $1,417,000 after buying an additional 509 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of IQVIA during the 3rd quarter worth $2,310,000. Finally, Arvest Bank Trust Division bought a new stake in IQVIA during the 3rd quarter worth $21,079,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on IQV shares. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Robert W. Baird decreased their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Bank of America cut their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.19.

IQVIA Stock Down 1.0 %

Shares of NYSE IQV traded down $1.97 during mid-day trading on Monday, reaching $197.09. 1,804,661 shares of the company’s stock were exchanged, compared to its average volume of 1,188,671. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $35.77 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.05 and a beta of 1.49. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The business has a fifty day simple moving average of $212.24 and a 200 day simple moving average of $224.20.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.